Boehringer Ingelheim and Proxygen have signed a collaboration and license agreement to allow the identification of molecular glue degraders against various oncogenic targets. Specifically, as reported by the company in a statement, the collaboration combines Proxygen’s unique molecular glue degradator discovery platform and its expertise in targeted protein degradation with Boehringer Ingelheim’s long-term strategy to provide the first innovative therapies. in its class for cancer patients. Likewise, Boehringer Ingelheim has announced the signing of a binding agreement to acquire all shares of NBE-Therapeutics, a privately-held Swiss biotechnology company in clinical phase focused on antibody-drug conjugates and advancing cancer-targeted therapies derived from its immunostimulatory platform iADC. NBE-Therapeutics’ lead compound, NBE-002, is currently in phase I clinical trials for triple negative breast cancer and other solid tumors.
Because we all need health … ConSalud.es
–
